Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics

AAPS Journal

Volumn 14, Issue 3, 2012, Pages 554-558

  Bumbaca, Daniela ^a   Boswell, C Andrew ^a   Fielder, Paul J ^a   Khawli, Leslie A ^a  

^a GENENTECH INC   (United States)

Author keywords

antibody; FcRn; glycosylation; isoelectric point; pharmacokinetics

Indexed keywords

ALEFACEPT; ANTIBODY; FC RECEPTOR; GOLIMUMAB; IMMUNOGLOBULIN G; INDIUM 111; MANNOSE; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AREA UNDER THE CURVE; BINDING AFFINITY; BIOEQUIVALENCE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; GLYCOSYLATION; HUMAN; IMMUNOLOGY; INJECTION SITE; ISOELECTRIC POINT; MACROMOLECULE; NEUROLOGY; NONHUMAN; ONCOLOGY; OPHTHALMOLOGY; PARTICLE SIZE; PH; RECEPTOR AFFINITY; REVIEW; SURFACE CHARGE; TISSUE DISTRIBUTION;

ANTIBODIES; GLYCOSYLATION; ISOELECTRIC POINT;

EID: 84862772871     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9369-y     Document Type: Review

References (40)

1. DR Mould KR Sweeney 2007 The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development Curr Opin Drug Discov Dev 10 1 84 96 1:CAS:528:DC%2BD2sXpsVGksw%3D%3D
2. G Sarmay J Lund Z Rozsnyay J Gergely R Jefferis 1992 Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor Mol Immunol 29 5 633 9 1533898 10.1016/0161-5890(92)90200-H 1:CAS:528:DyaK38XktVGkt7w%3D
3. IR Correia 2010 Stability of IgG isotypes in serum mAbs 2 3 221 32 20404539 10.4161/mabs.2.3.11788
4. JQ Dong DH Salinger CJ Endres JP Gibbs CP Hsu BJ Stouch, et al. 2011 Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction Clin Pharmacokinet 50 2 131 42 21241072 10.2165/11537430-000000000- 00000 1:CAS:528:DC%2BC3MXjtFCntLo%3D
5. W Wang EQ Wang JP Balthasar 2008 Monoclonal antibody pharmacokinetics and pharmacodynamics Clin Pharmacol Ther 84 5 548 58 18784655 10.1038/clpt.2008.170 1:CAS:528:DC%2BD1cXht1OisLvM
6. MA Tabrizi CM Tseng LK Roskos 2006 Elimination mechanisms of therapeutic monoclonal antibodies Drug Discov Today 11 1-2 81 8 16478695 10.1016/S1359-6446(05)03638-X 1:CAS:528:DC%2BD28XhsFygt70%3D
7. YA Yeung MK Leabman JS Marvin J Qiu CW Adams S Lien, et al. 2009 Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates J Immunol 182 12 7663 71 19494290 10.4049/jimmunol.0804182 1:CAS:528:DC%2BD1MXmslCnsb0%3D
8. R Deng KM Loyet S Lien S Iyer LE DeForge FP Theil, et al. 2010 Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys Drug Metab Dispos Biol Fate Chem 38 4 600 5 20071453 10.1124/dmd.109.031310 1:CAS:528:DC%2BC3cXhtVOgsrnN
9. LA Khawli B Biela P Hu AL Epstein 2003 Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors Hybridoma Hybridomics 22 1 1 9 10.1089/153685903321538026 1:CAS:528: DC%2BD3sXisleqtLY%3D
10. MS Dennis H Jin D Dugger R Yang L McFarland A Ogasawara, et al. 2007 Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent Cancer Res 67 1 254 61 17210705 10.1158/0008-5472.CAN-06-2531 1:CAS:528: DC%2BD2sXisFSmsQ%3D%3D
11. CA Boswell DB Tesar K Mukhyala FP Theil PJ Fielder LA Khawli 2010 Effects of charge on antibody tissue distribution and pharmacokinetics Bioconjug Chem 21 12 2153 63 21053952 10.1021/bc100261d 1:CAS:528:DC%2BC3cXhtlynsb3N
12. LA Khawli S Goswami R Hutchinson ZW Kwong J Yang X Wang, et al. 2010 Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats mAbs 2 6 613 24 20818176 10.4161/mabs.2.6.13333
13. MH Tao SL Morrison 1989 Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region J Immunol 143 8 2595 601 2507634 1:CAS:528:DyaL1MXmtFejtrs%3D
14. RJ Harris 2005 Heterogeneity of recombinant antibodies: linking structure to function Dev Biol 122 117 27 1:CAS:528:DC%2BD28XntVOgsw%3D%3D
15. AM Goetze YD Liu Z Zhang B Shah E Lee PV Bondarenko, et al. 2011 High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans Glycobiology 21 7 949 59 21421994 10.1093/glycob/ cwr027 1:CAS:528:DC%2BC3MXnsFWlur8%3D
16. JS Barrett JG Wagner SJ Fisher RL Wahl 1991 Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat Cancer Res 51 13 3434 44 1905196 1:STN:280:DyaK3M3nsFWjtA%3D%3D
17. Z Xu Q Wang Y Zhuang B Frederick H Yan E Bouman-Thio, et al. 2010 Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects J Clin Pharmacol 50 3 276 84 19940229 10.1177/0091270009340782 1:CAS:528:DC%2BC3cXjvFyrtrk%3D
18. D Ternant G Paintaud 2005 Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins Expert Opin Biol Ther 5 Suppl 1 S37 47 16187939 10.1517/14712598.5.1.S37 1:CAS:528:DC%2BD2MXhtVGgtrrI
19. JD Andya CC Hsu SJ Shire 2003 Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations AAPS pharmSci 5 2 E10 12866937 10.1208/ps050210
20. RK Jain 1999 Transport of molecules, particles, and cells in solid tumors Annu Rev Biomed Eng 1 241 63 11701489 10.1146/annurev.bioeng.1.1.241 1:CAS:528:DyaK1MXnvFyit7c%3D
21. AI Minchinton IF Tannock 2006 Drug penetration in solid tumours Nat Rev Cancer 6 8 583 92 16862189 10.1038/nrc1893 1:CAS:528:DC%2BD28XntFGlu7w%3D
22. M Tabrizi GG Bornstein H Suria 2010 Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease AAPS J 12 1 33 43 19924542 10.1208/s12248-009-9157-5 1:CAS:528:DC%2BC3cXisVGrtrs%3D
23. GM Thurber MM Schmidt KD Wittrup 2008 Factors determining antibody distribution in tumors Trends Pharmacol Sci 29 2 57 61 18179828 1:CAS:528:DC%2BD1cXhslOjsLw%3D
24. HJ Lee WM Pardridge 2003 Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging Bioconjug Chem 14 3 546 53 12757378 10.1021/bc0256648 1:CAS:528:DC%2BD3sXit1Ojt78%3D
25. F Herve N Ghinea JM Scherrmann 2008 CNS delivery via adsorptive transcytosis AAPS J 10 3 455 72 18726697 10.1208/s12248-008-9055-2
26. H Kobayashi N Le IS Kim MK Kim JE Pie D Drumm, et al. 1999 The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points Cancer Res 59 2 422 30 9927057 1:CAS:528:DyaK1MXntFOjtA%3D%3D
27. LA Khawli MS Glasky MM Alauddin AL Epstein 1996 Improved tumor localization and radioimaging with chemically modified monoclonal antibodies Cancer Biother Radiopharm 11 3 203 15 10851539 10.1089/cbr.1996.11.203 1:CAS:528:DyaK28XkvFWgsrw%3D
28. Y Zheng DB Tesar L Benincosa H Birnböck CA Boswell D Bumbaca, et al. 2012 Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration mAbs 4 2 0 1 10.4161/mabs.4.2.19387
29. T Igawa H Tsunoda T Tachibana A Maeda F Mimoto C Moriyama, et al. 2010 Reduced elimination of IgG antibodies by engineering the variable region Protein Eng Des Sel PEDS 23 5 385 92 10.1093/protein/gzq009 1:CAS:528: DC%2BC3cXks1Gqtrw%3D
30. DC Roopenian S Akilesh 2007 FcRn: the neonatal Fc receptor comes of age Nat Rev Immunol 7 9 715 25 17703228 10.1038/nri2155 1:CAS:528: DC%2BD2sXpsV2qtbw%3D
31. Y Zheng H Scheerens JC Davis Jr R Deng SK Fischer C Woods, et al. 2011 Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study Clin Pharmacol Ther 89 2 283 90 21191378 10.1038/clpt.2010.311 1:CAS:528:DC%2BC3MXpsVyltA%3D%3D
32. Y Kaneko F Nimmerjahn JV Ravetch 2006 Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 313 5787 670 3 16888140 10.1126/science.1129594 1:CAS:528:DC%2BD28Xnsl2hsbY%3D
33. Y Kanda T Yamada K Mori A Okazaki M Inoue K Kitajima-Miyama, et al. 2007 Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types Glycobiology 17 1 104 18 17012310 10.1093/glycob/ cwl057 1:CAS:528:DC%2BD28XhtlChtbrK
34. R Deng F Jin S Prabhu S Iyer 2012 Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 8 2 141 60 22248267 10.1517/17425255.2012.643868 1:CAS:528:DC%2BC38XhtV2itb8%3D
35. TA Millward M Heitzmann K Bill U Langle P Schumacher K Forrer 2008 Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice Biol J Int Assoc Biol Stand 36 1 41 7 1:CAS:528:DC%2BD1cXhtV2iu7w%3D
36. A Wright SL Morrison 1998 Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells J Immunol 160 7 3393 402 9531299 1:CAS:528:DyaK1cXitFWlt7w%3D
37. A Wright Y Sato T Okada K Chang T Endo S Morrison 2000 In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure Glycobiology 10 12 1347 55 11159927 10.1093/glycob/10.12. 1347 1:CAS:528:DC%2BD3MXlvFyhsg%3D%3D
38. MT Sweetser J Woodworth S Swan B Ticho 2006 Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept Dermatol Online J 12 3 1 16638415
39. ZH Xu QM Wang YL Zhuang B Frederick H Yan JC Marini, et al. 2009 Bioavailability of golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, administered subcutaneously at three different injection sites in healthy subjects Clin Pharmacol Ther 85 S1 S24
40. TA McDonald ML Zepeda MJ Tomlinson WH Bee IA Ivens 2010 Subcutaneous administration of biotherapeutics: current experience in animal models Curr Opin Mol Ther 12 4 461 70 20677097 1:CAS:528:DC%2BC3cXhtlaktL%2FP